Commissioning Brief - Background Information. Exercise training for people with pulmonary hypertension
|
|
- Annabel Reed
- 6 years ago
- Views:
Transcription
1 Commissioning Brief - Background Information HTA no 17/129 Exercise training for people with pulmonary hypertension This background document provides further information to support applicants for this call. It is intended to summarize what prompted the call and the existing evidence base, including relevant work from the HTA and wider NIHR research portfolio. It was researched and written on the basis of information from a search of relevant sources and databases, and in consultation with a number of experts in the field. Searches and information provided were up to date as of September Background information Source of topic This topic was first suggested at an engagement event with NHS England's Specialised Commissioning Group, with a focus on people with pulmonary arterial hypertension. A similar, but wider research recommendation came out of a newly published Cochrane review (Morris 2017), 1 where the patient groups of interest are people with pulmonary hypertension of any cause. This research brief will follow the research recommendation specified in the Cochrane review. Patient group Pulmonary hypertension (PH) is a condition that is characterised by an increase in mean pulmonary arterial pressure ( 25 mm Hg at rest). It can be caused by or associated with a variety of conditions, but can also be inherited or idiopathic. Patients with PH usually present with progressive dyspnoea or other nonspecific symptoms, e.g. weakness and tiredness. PH is a serious condition that can cause right heart failure. It can progress rapidly and is associated with high morbidity and mortality. People of any age can be affected, including adults, children and neonates. The definition of PH is evolving, which makes it difficult to define incidence and prevalence. International guidelines currently classify PH into the following five clinical groups: Group 1: Pulmonary arterial hypertension (PAH). This form of PH is rare, with an estimated prevalence of cases per million people; incidence is estimated at cases per million people per year. In the UK, most of the patients diagnosed with PAH are managed in one of the seven specialist centres. Group 2: PH due to left heart disease (e.g. systolic dysfunction, diastolic dysfunction, valvular disease, congenital cardiomyopathies, pulmonary vein stenosis). PH occurs in 7-83% of people with diastolic heart failure. Group 3: PH due to lung diseases or hypoxia, or both (e.g. COPD, interstitial lung disease, sleepdisordered breathing, alveolar hypoventilation disorders, chronic exposure to high altitude, or developmental abnormalities). Group 3 PH is found in 18-50% of patients assessed for transplantation or lung volume reduction surgery. Group 4: chronic thromboembolic PH (CTEPH). Incidence is estimated to be cases per million people per year. Between 0.5% and 4% of patients with acute pulmonary embolism subsequently develop CTEPH. Group 5: PH with unclear multifactorial mechanisms. Page 1 of 5
2 The exact number of people living with PH in the UK is not known. A recent audit of PH services in England and Scotland concluded that more than 9000 patients are currently managed by one of the seven specialist centres. However, patients with milder forms of PH may be managed outside these centres. Some experts believe that the condition is under-diagnosed, given its unspecific symptoms and gradual onset. [Sources: Patient.info Pulmonary Hypertension Association UK National Audit of Pulmonary Hypertension, published on 23 March NICE and other guidance European Society of Cardiology (ESC) Clinical Practice Guideline: Pulmonary Hypertension (Guidelines on Diagnosis and Treatment of). Published These guidelines suggest that treatment of underlying conditions should be optimised in the first instance, followed by PH specific drugs. For pulmonary arterial hypertension (PAH), supervised exercise training should be considered in physically deconditioned PAH patients under medical therapy. The guideline authors acknowledge that the supporting evidence is of moderate strength and quality. They point out that there is uncertainty around the best method of exercise therapy, the intensity, and the duration of exercise programmes. The guidelines recommend that patients should be in stable clinical condition before taking up exercise therapy. Exercise therapy is not mentioned in the context of any of the remaining PH groups. There are currently no UK clinical guidelines for pulmonary hypertension in adults. NICE has published two interventional guidelines (IPG) and one evidence summary on unlicensed and off-label medicines (ESUOM) in this disease area (not relevant to the research question). IPG554 Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Published date: April IPG505 Telemetric adjustable pulmonary artery banding for pulmonary hypertension in infants with congenital heart defects Published date: November 2014 ESUOM51 Pulmonary hypertension in neonates: sildenafil Published date: March 2016 Current practice and proposed intervention Current practice As described above, treatment of underlying conditions should be optimised in the first instance, followed by PH specific drugs as required. In the UK, patients with advanced or severe forms of PH should be referred to a specialist centre. There are six PH centres in England, and one in Scotland. Some people with PH may be offered surgery, such as pulmonary endarterectomy, balloon pulmonary angioplasty, atrial septostomy, lung transplant, or heart-lung transplant. Proposed intervention There is some evidence of modest quality to suggest clinical and economic benefits of exercise therapy in people with PAH (Group 1 PH). However, only very little evidence exists on the effects of exercise training in other, larger PH groups, such as those with underlying or associated heart or lung conditions. A recent Cochrane review 1 of studies investigating exercise-based rehabilitation programmes for pulmonary hypertension identified a variety of exercise programmes. These included elements of aerobic and strength training, with the intention to improve patients' compromised aerobic capacity and muscle strength. Study participants engaged in cycling or walking exercise of 20 to 40 minutes duration (aerobic training) and/or in sets of repetitive muscle exercises of upper and lower limbs (strength training). Programmes were offered in in-patient and outpatient settings, but for the purpose of this research topic, only outpatient settings are of interest. The exercise programmes reviewed in the Cochrane review are similar to those that may already be offered to people with chronic lung diseases. They are considered safe and effective in these patients. However, until recently, guidelines discouraged exercise in people with PH, and some clinicians may be concerned about adverse effects in people with PH, such as worsening of symptoms and of cardiac function during exercise and/or in the longer term. Page 2 of 5
3 More recent guidelines encourage people with PH to be active within their limits. The Cochrane review 1 'suggests that supervised exercise-based rehabilitation is likely to be safe for people with pulmonary hypertension (PH) who are stable on medical therapy and can lead to meaningful improvements in exercise capacity.' The review also suggests that people with PH may be able to receive exercise therapy through participation in standard pulmonary or heart failure rehabilitation programmes, albeit with modified exercise prescription and monitoring practices. There is currently no evidence available to guide exercise therapy in this patient group, e.g. regarding dose, intensity, and supervision. There is also a need to assess the clinical and economic benefits as well as the potential harms of exercise therapy in different PH groups, especially in those groups that are under-researched. The suggested research is expected to provide information for physicians, patients and commissioners, and guide decision-making in the management of people with PH. Completed research Evidence Synthesis One Cochrane review (the source of this research topic) and one German cost-effectiveness analysis were identified. Exercise-based rehabilitation programmes for pulmonary hypertension. Morris (2017). 1 This Cochrane review assessed the efficacy and safety of supervised exercise-based rehabilitation compared with usual care or no exercise-based rehabilitation for people with any type of pulmonary hypertension. It included six RCTs (206 participants; searches up to August 2016), and data were extracted from five studies (165 participants). The majority of participants were Group 1 PH (i.e. those with pulmonary arterial hypertension), and a small number were Group 4 PH (chronic thromboembolic PH). None of the studies included participants from other PH groups, such as those with associated cardiac or lung conditions. The study durations were short and ranged from three to 15 weeks. The quality of evidence was generally low. No studies reported allocation concealment, and there was potential selection bias. Exercise programmes included both inpatient- and outpatient-based rehabilitation. The exercise protocols consisted mainly of walking or cycling, usually with resistance exercises for the upper and lower limbs. These protocols are similar to those recommended for standard pulmonary and cardiac rehabilitation programmes. Some studies included stretching, breathing techniques, body perception, yoga, and/or strengthening of respiratory muscles as additional components. Main results: The included studies reported large and clinically significant improvements in exercise capacity, using validated assessment tools. However, due to a high degree of heterogeneity across trials, it was not possible to determine whether these effects were due to differences in study populations (PAH vs. other), settings (inpatient vs. outpatient) or severity of the disease. There was also improvement in health-related quality of life, although it was not clear whether the magnitude of these changes was clinically important. Only one adverse event was reported. Most of the secondary outcomes pre-specified by the authors were not reported (cardiopulmonary haemodynamics, functional class, B-type natriuretic peptide, effects of rehabilitation, time to clinical worsening or mortality). The authors conclude that the limitations of the included studies make it difficult to generalise these results. They suggest that future trials should investigate exercise-based rehabilitation across the spectrum of people with PH, i.e. such studies should ideally include participants from all PH groups and of all grades of disease severity. Economic evaluation of exercise training in patients with pulmonary hypertension. Ehlken (2014). 3 The purpose of this German economic analysis was to analyse the impact of exercise training on healthcare costs in patients with PH. The study followed two cohorts of people with PH (types of PH not reported). A prospective cohort (N=58) received exercise therapy in addition to routine medical treatment. The comparator group, a retrospective age- and gender-matched cohort (N=46), had received routine medical treatment only. During a follow-up of 24±12 months, the exercise group had significantly better survival rates at one and three years and less worsening events (death, lung transplantation, hospitalization due to PH, new PAH-targeted medication) than the control group (15 vs. 25 events, p < 0.05). This led to lower Page 3 of 5
4 estimated healthcare costs of 657 (approx. 570) within a period of 2 years. The savings were mainly due to reduced medication costs. Primary Research We identified one new RCT that was not included in the Cochrane review. Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi + 12 trial. Gonzalez-Saiz (2017). 4 This small Spanish RCT investigated the effects of an eight-week supervised inpatient intervention combining muscle resistance, aerobic and inspiratory pressure-load exercises. Outcomes of interest were upper and lower-body muscle power and other functional variables. Participants were patients with pulmonary arterial hypertension or with chronic thromboembolic pulmonary hypertension (N=40). Adherence to training sessions was good, and muscle power (the primary outcome measure) improved during the programme. There were no adverse events due to exercise. Research in progress Evidence Synthesis Which physiotherapeutic treatment influences the improvement of the quality of life of adult patients with pulmonary arterial hypertension? (Pereira & Machado). Anticipated completion date: 01 September PROSPERO 2017:CRD This review will include studies in people with pulmonary arterial hypertension. The patient groups specified in this research brief will not be represented in this review. Primary Research A small number of ongoing studies were identified. These are not expected to answer this topic's research question. UK STUDIES NAtional cohort study of Idiopathic AnD heritable pulmonary arterial hypertension This a multicentre observational cohort study aims to explore the genetic causes of PAH. Participants are those with heritable and idiopathic pulmonary arterial hypertension and some of their relatives. Target sample size: 3,600. Estimated completion: 31 August Funders: British Heart Foundation and Medical Research Council (MRC). ISRCTN / NCT The Effect of Adding Exercise Training to Optimal Therapy in PAH The aims of this small RCT are (1) to demonstrate that exercise training can enhance exercise capacity and quality of life when added to optimal drug therapy; and (2) to explore mechanisms of exercise limitation and factors that improve with training, assessing cardiac function, skeletal muscle function, autonomic function, respiratory muscle strength, and serum and muscle profile of inflammation. Target sample size: 30 (15 in each arm). Estimated completion: November UK single centre randomised study (Glasgow). Funder: NHS. NCT Habitual physical activity and exercise capacity in pulmonary hypertension Target sample size: 15. Estimated completion: 28/02/2017. Follow-up: 15 weeks. Funder: Newcastle upon Tyne NHS Foundation Trust, Freeman Hospital. ISRCTN This trial is completed, but not yet published. Only little detail is provided in the study registration, but this appears to be a nonrandomised, single-centre pilot study with a mechanistic research interest at a muscular and cellular level (the CI is an Associate Clinical Researcher at the Institute of Cellular Medicine, Newcastle University). Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension (STEP in PH) Target sample size: 42. Expected completion: June Imperial College Healthcare NHS Trust. NCT The purpose of the study is to demonstrate whether providing patients with their daily step count can increase their levels of daily activity if they have some basic targets to achieve. Investigators also wish to compare the effects of this approach in increasing daily physical activity, with the benefit gained when a drug therapy for pulmonary hypertension is initiated, in patients that have just been diagnosed. Eligibility: Nice Classification Groups 1 and 4 Pulmonary Hypertension (pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension). Page 4 of 5
5 INTERNATIONAL STUDIES Effect of Exercise Training in Patients With Pulmonary Hypertension The objectives of this study are to test a 'standardized 3 week in-hospital exercise training program' and to investigate the effects of oxygen administration during training. Target sample size: 32. Estimated completion: December Follow-up: 12 months. Single centre randomised study. Switzerland. NCT Aerobic Exercise Training in Pulmonary Arterial Hypertension This study investigates the effects of upper extremity aerobic exercise training in patients with pulmonary arterial hypertension. Target sample size: 30. Estimated completion: December Follow-up: 6 weeks. Single centre randomised study. Turkey. NCT Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life and Right Ventricular Function in Severe Pulmonary Hypertension Target sample size: 90. Estimated completion: June Current status not known (register was last updated in July 2014). Follow-up: 15 weeks. Single centre RCT. Germany. NCT Exercise Training in Pulmonary Hypertension (ExTra_PH): A randomised controlled trial examining short and long-term outcomes of an outpatient-based exercise training in pulmonary hypertension The study will investigate the safety and effectiveness of exercise training for people with PH (subgroups not specified, but participants will be recruited from tertiary centres). Follow-up: 2 years min. Target sample size: 50. Estimated completion: Not reported. According to the trial register, the trial is not yet recruiting (last checked: 29/03/2017). Australia. ACTRN NIHR Evaluation Trials and Studies (NETS) research NETS programmes have not yet funded any projects in this disease area, with the exception of a NICE TAR (05/24/01 Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension in adults: a systematic review and economic evaluation; published). References 1. Morris NR, Kermeen FD, Holland AE. Exercise-based rehabilitation programmes for pulmonary hypertension. The Cochrane database of systematic reviews 2017;1:CD doi: / CD pub2 2. Galie N, Humbert M, Vachiery JL, et al ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European heart journal 2016;37(1):67-+. doi: /eurheartj/ehv Ehlken N, Verduyn C, Tiede H, et al. Economic Evaluation of Exercise Training in Patients with Pulmonary Hypertension. Lung 2014;192(3): doi: /s Gonzalez-Saiz L, Fiuza-Luces C, Sanchis-Gomar F, et al. Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial. Int J Cardiol 2017;231: doi: /j.ijcard Page 5 of 5
22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment
22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School
More informationRiociguat for chronic thromboembolic pulmonary hypertension
Riociguat for chronic thromboembolic pulmonary hypertension This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION REVIEW & UPDATE Olga M. Fortenko, M.D. Pulmonary & Critical Care Medicine Pulmonary Vascular Diseases Sequoia Hospital 650-216-9000 Olga.Fortenko@dignityhealth.org Disclosures None
More informationQOF indicator area: Chronic Obstructive Pulmonary disease (COPD)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Chronic Obstructive Pulmonary Disease QOF indicator area:
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationExercise-based rehabilitation programmes for pulmonary hypertension [Intervention Review]
Exercise-based rehabilitation programmes for pulmonary hypertension [Intervention Review] Author Morris, Norman, Kermeen, Fiona, Holland, Ann Published 2017 Journal Title Cochrane Database of Systematic
More informationClinical Commissioning Policy: Selexipag for treating pulmonary arterial hypertension (all ages)
Clinical Commissioning Policy: Selexipag for treating pulmonary arterial hypertension (all ages) NHS England Reference: 170065P 1 NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationIn keeping with the Scottish Diabetes Group criteria, use should be restricted to those who:
Advice Statement 009-18 July 2018 Advice Statement What is the clinical and cost effectiveness of Freestyle Libre flash glucose monitoring for patients with diabetes mellitus treated with intensive insulin
More informationScottish Medicines Consortium
Scottish Medicines Consortium sildenafil, 20mg (as citrate) tablets (Revatio ) No. (596/10) Pfizer Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationNHS England. Evidence review: Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
NHS England Evidence review: Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) 1 NHS England Evidence review: Balloon pulmonary angioplasty for inoperable
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationPulmonary Hypertension: Definition and Unmet Needs
Heart Failure Center Hadassah University Hospital Pulmonary Hypertension: Definition and Unmet Needs Israel Gotsman The Heart Failure Center Hadassah University Hospital I DO NOT have a financial interest/
More informationCommissioning for Better Outcomes in COPD
Commissioning for Better Outcomes in COPD Dr Matt Kearney Primary Care & Public Health Advisor Respiratory Programme, Department of Health General Practitioner, Runcorn November 2011 What are the Commissioning
More informationClinical Commissioning Policy Proposition: Selexipag in the treatment of Pulmonary Arterial Hypertension
Clinical Commissioning Policy Proposition: Selexipag in the treatment of Pulmonary Arterial Hypertension Reference: NHS England A11X04/01 Information Reader Box (IRB) to be inserted on inside front cover
More informationGOVERNING BODY REPORT
GOVERNING BODY REPORT DATE OF MEETING: 20th September 2012 TITLE OF REPORT: KEY MESSAGES: NHS West Cheshire Clinical Commissioning Group has identified heart disease as one of its six strategic clinical
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationPulmonary Arterial Hypertension: The Approach to Management in 2019
Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical
More informationPreoperative tests (update)
National Institute for Health and Care Excellence. Preoperative tests (update) Routine preoperative tests for elective surgery NICE guideline NG45 Appendix C: April 2016 Developed by the National Guideline
More informationELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY
ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents Eligibility criteria for Pulmonary Arterial Hypertension therapy...2-6 Initial Application for funding of Pulmonary Arterial Hypertension
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationSurveillance report Published: 8 June 2017 nice.org.uk. NICE All rights reserved.
Surveillance report 2017 Antenatal and postnatal mental health: clinical management and service guidance (2014) NICE guideline CG192 Surveillance report Published: 8 June 2017 nice.org.uk NICE 2017. All
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationResource impact report: Eating disorders: recognition and treatment (NG69)
Resource impact report: Eating disorders: recognition and treatment (NG69) Published: May 2017 Summary This report looks at the resource impact of implementing NICE s guideline on eating disorders: recognition
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews A systematic review of behaviour change interventions targeting physical activity, exercise and HbA1c in adults with type 2 diabetes Leah
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationTherapeutic approaches in P(A)H and the new ESC Guidelines
Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Highly Specialised Technology Evaluation
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Highly Specialised Technology Evaluation Drisapersen for treating Duchenne muscular Draft scope (pre-referral) Draft remit/evaluation objective
More informationΕιδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών
Ειδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών . Updated Clinical Classification of Pulmonary Hypertension
More informationMeta-analyses: analyses:
Meta-analyses: analyses: how do they help, and when can they not? Lee Hooper Senior Lecturer in research synthesis & nutrition l.hooper@uea.ac.uk 01603 591268 Aims Systematic Reviews Discuss the scientific
More informationSetting The setting was a hospital. The economic study was carried out in Australia.
Coronary artery bypass grafting (CABG) after initially successful percutaneous transluminal coronary angioplasty (PTCA): a review of 17 years experience Barakate M S, Hemli J M, Hughes C F, Bannon P G,
More informationPulmonary Rehab Sheffield Community Active Programmes Team. Ursula Freeman Physiotherapist and Team Leader
Pulmonary Rehab Sheffield Community Active Programmes Team Ursula Freeman Physiotherapist and Team Leader Aims Update on most recent evidence PR National Audit Engaging with patients What we offer in Sheffield
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More informationNHS GG&C Introduction of Freestyle Libre flash glucose monitoring system
NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system The Freestyle Libre flash glucose monitoring system is a sensor based, factory-calibrated system that measures interstitial fluid
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationInterventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600
Endobronchial valve insertion to reduce lung volume in emphysema Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600 Your responsibility This guidance represents
More informationDates to which data relate The effectiveness and resource use data refer to the period 1983 to The price year was 1994.
Cost-effectiveness analysis of stents, balloon angioplasty, and surgery for the treatment of branch pulmonary artery stenosis Trant C A, O'Laughlin M P, Ungerleider R M, Garson A Record Status This is
More informationClinical Commissioning Policy: Selexipag in the treatment of Pulmonary Arterial Hypertension
Clinical Commissioning Policy: Selexipag in the treatment of Pulmonary Arterial Hypertension Reference: NHS England: 16017/P NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews What is the application of ultrasound imaging in primary care for musculoskeletal disorders? Mark Karaczun, Toby Smith, Robert Fleetcroft,
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationReferral Forms for TYVASO and REMODULIN
Referral Forms for TYVASO and REMODULIN HOW TO GET STARTED Tyvaso and Remodulin are available only through select Specialty Pharmacy Services (SPS) providers. Follow these 5 simple steps to complete each
More informationIn focus The paediatric PAH population Clinicians Perspectives
In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire
More informationConcentration and choice in the provision of hospital services: summary report NHS Centre for Reviews and Dissemination
Concentration and choice in the provision of hospital services: summary report NHS Centre for Reviews and Dissemination Authors' objectives To undertake systematic reviews of the literature on the relationship
More informationPulmonary Arterial Hypertension: A Journey to Lung Transplant
PH GRAND ROUNDS Pulmonary Arterial Hypertension: A Journey to Lung Transplant Section Editor Deborah J. Levine, MD Bravein Amalakuhan, MD Pulmonary and Critical Care Medicine Fellow University of Texas
More informationCosting Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)
Putting NICE guidance into practice Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Published: June 2014 This costing report accompanies the clinical
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationSelective Dorsal Rhizotomy (SDR) Scotland Service Pathway
Selective Dorsal Rhizotomy (SDR) Scotland Service Pathway This pathway should to be read in conjunction with the attached notes. The number in each text box refers to the note that relates to the specific
More informationCochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library)
A systematic review of smoking cessation and relapse prevention interventions in parents of babies admitted to a neonatal unit (after delivery) Divya Nelson, Sarah Gentry, Caitlin Notley, Henry White,
More informationThe growing interest in pulmonary hypertension (PH) in
Eur Respir J 2010; 36: 986 990 DOI: 10.1183/09031936.00038410 CopyrightßERS 2010 EDITORIAL Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed N. Galiè, M. Palazzini and
More informationPriorities for implementation research
Leeds Institute of Health Sciences Priorities for implementation research Robbie Foy 1. Ensure rigour For example, in evaluating effectiveness 1. Ensure rigour The randomised trial is the worst form of
More informationNational Diabetes Treatment and Care Programme
National Diabetes Treatment and Care Programme Introduction to and supporting documentation for VALUE BASED TRANSFORMATION FUNDING SITE SELECTION December 2016 1 Introduction and Contents The Planning
More informationProof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease. Produced on behalf of NHS Wales and Welsh Government
Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease Produced on behalf of NHS Wales and Welsh Government April 2018 Table of Contents Introduction... 3 Variation in health services...
More informationPULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER
PULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER OUTLINE Brief review of WHO Group Classification Scheme Subgroups we ll focus on: WHO Group I Pulmonary Arterial
More informationStart of Phase IIIb Study with Bayer s Riociguat in PAH Patients Who Demonstrate an Insufficient Response to PDE-5 Inhibitors
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Pulmonary Arterial Hypertension (PAH): Start of Phase IIIb Study with Bayer
More informationPutting NICE guidance into practice. Resource impact report: Post-traumatic stress disorder (NG116)
Putting NICE guidance into practice Resource impact report: Post-traumatic stress disorder (NG116) Published: December 2018 Summary This report focuses on the recommendations from the NICE guideline on
More informationNational Optimal Lung Cancer Pathways. Dr Sadia Anwar Nottingham University Hospitals NHS Trust Clinical Lead for Lung Cancer
National Optimal Lung Cancer Pathways Dr Sadia Anwar ttingham University Hospitals NHS Trust Clinical Lead for Lung Cancer Overview How NOLCP evolved How it relates to national guidance Pathways Implementation
More informationHealth technology The use of ultrasonography in the diagnosis and management of developmental hip dysplasia.
Ultrasonography in the diagnosis and management of developmental hip dysplasia (UK Hip Trial): clinical and economic results of a multicentre randomised controlled trial Elbourne D, Dezateux, Arthur R,
More informationGuideline scope Neonatal parenteral nutrition
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Neonatal parenteral nutrition The Department of Health in England has asked NICE to develop a new guideline on parenteral nutrition in
More informationSA XXXX Special Authority for Subsidy
SA XXXX Special Authority for Subsidy Special authority approved by the Pulmonary Arterial Hypertension (PAH) Panel. Application forms can be obtained from PHARMAC s website: www.pharmac.govt.nz or: PAH
More informationBritish Association of Stroke Physicians Strategy 2017 to 2020
British Association of Stroke Physicians Strategy 2017 to 2020 1 P age Contents Introduction 3 1. Developing and influencing local and national policy for stroke 5 2. Providing expert advice on all aspects
More informationFrom Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension
From Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension Dr Rachel Davies Respiratory Physician National Pulmonary Hypertension Service Hammersmith Hospital Royal College of Physicians
More informationPulmonary Hypertension: Clinical Features & Recent Advances
Pulmonary Hypertension: Clinical Features & Recent Advances Lisa J. Rose-Jones, MD Assistant Professor of Medicine, Division of Cardiology Advanced Heart Failure/Cardiac Transplantation & Pulmonary Hypertension
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Closed reduction methods for acute anterior shoulder dislocation [Cochrane Protocol] Kanthan Theivendran, Raj Thakrar, Subodh Deshmukh,
More informationAcute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?
Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How? Teresa De Marco, MD University of California, San Francisco Disclosures: Grants/Research: United Therapeutics, Lung Biotechnology,
More informationCommissioning Brief - Background Information. Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of COPD
Commissioning Brief - Background Information Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of COPD HTA no 17/128 This background document provides further information to
More informationUpdate on Pulmonary Rehabilitation Programme. HA Convention Dr. Wong WY, Ida Haven of Hope Hospital 8 May 2018
Update on Pulmonary Rehabilitation Programme HA Convention Dr. Wong WY, Ida Haven of Hope Hospital 8 May 2018 Impacts of COPD to patients Increase dyspnoea Limitation of activity Decrease quality of life
More informationPulmonary vascular remodelling: causes, mechanisms and consequences
Pulmonary vascular remodelling: causes, mechanisms and consequences Ralph Schermuly Department of Pulmonary Pharmacotherapy University of Giessen and Marburg Lung Center email: ralph.schermuly@ugmlc.de
More informationREVATIO (sildenafil)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationTeaching Round Claudio Sartori
Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2
More informationPulmonary Hypertension: ICD-10 I27.0, I27.2
Dr Manish Barman, MD. Membership and Affiliations ESC, European association of cardiovascular prevention and rehabilitation. Acute Cardiovascular Care Association. ESC, Working Group on Hypertension &
More informationClass Update with New Drug Evaluation: Drugs for Pulmonary Arterial Hypertension
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Medical technology guidance FINAL SCOPE ENDURALIFE-powered CRT-D devices for the treatment of heart failure 1 Technology 1.1 Description of the technology
More informationRecruitment and Consenting
1 Recruitment and Consenting MOP Chapter 4 NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health with support from
More informationPaediatric PAH in the current era
Paediatric PAH in the current era Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine Paediatric PAH in the current era & A Gap Analysis Dunbar Ivy, MD The
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency London, 18 December 2008 Doc. Ref. EMEA/CHMP/EWP/356954/2008 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT CHMP GUIDELINE ON THE CLINICAL INVESTIGATIONS OF MEDICINAL
More informationThe Sildenafil Controversy
The Sildenafil Controversy Chronology European Development Revatio (Sildenafil) Orphan Drug designation: 03.12.2003 & 27.02.2007 Paediatric Investigation Plan: 17.03.2010 Marketing Authorisation in EU:
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationNeonatal and Pediatric Pulmonary Vascular Disease
Neonatal and Pediatric Pulmonary Vascular Disease Emma Olson, MS, ARNP Pediatric Cardiology Nurse Practitioner Canadian Respiratory Conference April 14, 2018 Financial Interest Disclosure (over the past
More informationIs there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life?
Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life? Summary of the evidence located: According to the NICE guideline on Chronic Obstructive Pulmonary Disease
More informationTechnology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta459
Collagenase clostridium histolyticum for treating Dupuytren's contracture Technology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta459 NICE 2017. All rights reserved. Subject to Notice
More informationHow effective are national strategies for getting evidence into practice?
How effective are national strategies for getting evidence into practice? Dr Gillian Leng Deputy Chief Executive, NICE Areas to cover Getting NICE guidance into practice Challenges National strategy Impact
More informationNational Institute for Health and Clinical Excellence. Drugs for the treatment of pulmonary arterial hypertension
Comments on the draft scope: second consultation October 2006 Drugs for the treatment of pulmonary arterial hypertension Section Consultees Comments Action Background information Actelion Pharmaceuticals
More informationPRESS RELEASE. New NICE guidance will improve diagnosis and treatment of chronic heart failure
Tel: 0845 003 7782 www.nice.org.uk Ref: 2010/118 ISSUED: WEDNESDAY, 25 AUGUST 2010 PRESS RELEASE New NICE guidance will improve diagnosis and treatment of chronic heart failure The National Institute for
More informationExtracorporeal shockwave therapy for refractory Achilles tendinopathy
Extracorporeal shockwave therapy for refractory Achilles Issued: August 2009 www.nice.org.uk/ipg312 NHS Evidence has accredited the process used by the NICE Interventional Procedures Programme to produce
More informationEvidence Briefing for NHS Bradford and Airedale. Physical health monitoring for people with schizophrenia or other serious mental illness
Evidence Briefing for NHS Bradford and Airedale Physical health monitoring for people with schizophrenia or other serious mental illness The NICE clinical guideline on schizophrenia 1 recommends that GPs
More informationData extraction. Specific interventions included in the review Dressings and topical agents in relation to wound healing.
Systematic reviews of wound care management: (2) dressings and topical agents used in the healing of chronic wounds Bradley M, Cullum N, Nelson E A, Petticrew M, Sheldon T, Torgerson D Authors' objectives
More informationA Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom
A Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom Global perspective on heart failure: what needs to change? Martin R Cowie Professor of Cardiology National
More informationADCIRCA (tadalafil) The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationBreathing exercises for chronic obstructive pulmonary disease (Protocol)
Breathing exercises for chronic obstructive pulmonary disease (Protocol) Holland AE, Hill C, McDonald CF This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration
More informationNational Optimal Lung Cancer Pathway
National Optimal Lung Cancer Pathway This document was produced by the Lung Clinical Expert Group 2017 Document Title: National Optimal Lung Cancer Pathway and Implementation Guide Date of issue: August
More information